Antibodies, Monoclonal, Murine-Derived
-
Subject Areas on Research
-
A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
-
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia.
-
A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo.
-
A novel subset of memory B cells is enriched in autoreactivity and correlates with adverse outcomes in SLE.
-
A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.
-
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma.
-
Acquired vulvar lymphangioma circumscriptum: a comparison of 12 cases with Crohn's associated lesions or radiation therapy induced tumors.
-
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide (RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
-
Addition of rituximab to chemotherapy overcomes the negative prognostic impact of cyclin E expression in diffuse large B-cell lymphoma.
-
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
-
Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT.
-
Anti-CD20 monoclonal antibody (rituximab) therapy for acute cardiac humoral rejection: a case report.
-
Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
-
Antiviral antibodies are necessary for control of simian immunodeficiency virus replication.
-
Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).
-
Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients.
-
B cell-directed therapies for autoimmune disease and correlates of disease response and relapse.
-
B cells in chronic graft-versus-host disease.
-
B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions.
-
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
-
B-lymphocyte contributions to human autoimmune disease.
-
Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
-
Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.
-
CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.
-
CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies.
-
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.
-
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
-
Carbamylation of immunoglobulin abrogates activation of the classical complement pathway.
-
Cardiogenic shock complicates successful treatment of refractory thrombotic thrombocytopenia purpura with rituximab.
-
Cellular targeting in autoimmunity.
-
Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.
-
Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.
-
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma.
-
Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.
-
Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.
-
Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature.
-
Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study.
-
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas.
-
Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
-
Defining Potential Vaccine Targets of Haemophilus ducreyi Trimeric Autotransporter Adhesin DsrA.
-
Designs for randomized phase II clinical trials with two treatment arms.
-
Differential effects of donor-specific alloantibody.
-
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CALGB 9581.
-
Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
-
Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
-
Effect of B-cell depletion on viral replication and clinical outcome of simian immunodeficiency virus infection in a natural host.
-
Efficacy of remission-induction regimens for ANCA-associated vasculitis.
-
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
-
Generation and characterization of a IgG monoclonal antibody specific for GM3 (NeuGc) ganglioside by immunizing β3Gn-T5 knockout mice.
-
Good and bad memories following rituximab therapy.
-
HIV-1 antibodies and vaccine antigen selectively interact with lipid domains.
-
Hairy cell leukemia: an elusive but treatable disease.
-
Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).
-
Hepatitis C virus-related cryoglobulinemic vasculitis: emerging trends in therapy.
-
How I treat thrombocytopenia in pregnancy.
-
Identification of compounds that enhance the anti-lymphoma activity of rituximab using flow cytometric high-content screening.
-
Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
-
Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
-
Immunosuppressive therapies in myasthenia gravis.
-
Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging.
-
Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002.
-
Improving outcomes in advanced DLBCL: systemic approaches and radiotherapy.
-
Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
-
Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.
-
Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain.
-
Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial.
-
MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
-
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program.
-
Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma.
-
Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer--a study of CALGB 9581 and 89803.
-
Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
-
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
-
NF-κB p50 activation associated with immune dysregulation confers poorer survival for diffuse large B-cell lymphoma patients with wild-type p53.
-
New insights and therapeutics for immune-mediated thrombocytopenia.
-
Non-Hodgkin's lymphomas, version 2.2014.
-
Ofatumumab-based chemoimmunotherapy is effective and well tolerated in patients with previously untreated chronic lymphocytic leukemia (CLL).
-
Outcomes and costs of autologous stem cell mobilization with chemotherapy plus G-CSF vs G-CSF alone.
-
Outcomes of nonsevere relapses in antineutrophil cytoplasmic antibody-associated vasculitis treated with glucocorticoids.
-
Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
-
Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
-
Persistence and selection of an expanded B-cell clone in the setting of rituximab therapy for Sjögren's syndrome.
-
Persistent antibody depletion after rituximab in three children with autoimmune cytopenias.
-
Phase I studies of interleukin (IL)-2 and rituximab in B-cell non-hodgkin's lymphoma: IL-2 mediated natural killer cell expansion correlations with clinical response.
-
Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma.
-
Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia.
-
Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness.
-
Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma.
-
Podocyte effacement closely links to suPAR levels at time of posttransplantation focal segmental glomerulosclerosis occurrence and improves with therapy.
-
Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.
-
Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
-
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
-
Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.
-
Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.
-
Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment.
-
Protein modification by deamidation indicates variations in joint extracellular matrix turnover.
-
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).
-
Rapid identification of monospecific monoclonal antibodies using a human proteome microarray.
-
Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
-
Recent advances in de novo CD5+ diffuse large B cell lymphoma.
-
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease.
-
Reduced expression of TRIM21/Ro52 predicts poor prognosis in diffuse large B-cell lymphoma patients with and without rheumatic disease.
-
Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice.
-
Relapse of thrombotic thrombocytopenic purpura: is it a continuum of disease?
-
Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia.
-
Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
-
Rituximab as monotherapy for elicited xenoreactive antibody responses.
-
Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP).
-
Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live?
-
Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome.
-
Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.
-
Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.
-
Rituximab in lymphocyte predominance Hodgkin's disease: a case series.
-
Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.
-
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
-
Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
-
Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
-
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
-
Rituximab-associated progressive multifocal leukoencephalopathy after lung transplantation.
-
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
-
Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies.
-
Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.
-
Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program.
-
Small lymphocytic lymphoma presenting as a paraneoplastic syndrome with acute central nervous system demyelination.
-
Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.
-
Stromal gene signatures in large-B-cell lymphomas.
-
Successful treatment of refractory childhood pemphgus vulgaris with anti-CD20 monoclonal antibody (rituximab).
-
Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease.
-
Sustained elite suppression of replication competent HIV-1 in a patient treated with rituximab based chemotherapy.
-
Targeted therapies for cancer 2004.
-
Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation.
-
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review.
-
Treatment options for newly diagnosed patients with chronic lymphocytic leukemia.
-
Unusual clinical and immunologic manifestations of transplacentally acquired maternal T cells in severe combined immunodeficiency.
-
Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.
-
Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
-
[18F]-fluorodeoxyglucose positron emission tomography combined with computed tomography detection of asymptomatic late pulmonary toxicity in patients with non-Hodgkin lymphoma treated with rituximab-containing chemotherapy.
-
p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.
-
Keywords of People